UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months
July 20, 2016 9:48 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results. The analyst continues to expected FDA approval in the next few months.
Gilson commented, "Sarepta on July 19 reported 2Q16 financial results, ending the... More
Stocks with Implied Volatility Movement
July 18, 2016 5:11 AM EDTSarepta Therapeutics (SRPT), Rite Aid (RAD) implied volatility is above its IV index mean
... MoreSanthera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - Oppenheimer
July 15, 2016 10:58 AM EDTOppenheimer analyst, Michele Gilson reiterated her Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) after Santhera announced today that the FDA did not support its plans to file an NDA for Raxone (idebenone) for the treatment of DMD. We do not view this as a... More
